- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02937701
Study to Assess if ABP710 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis Compared to Infliximab
A Randomized, Double-Blind Phase 3 Study to Assess the Efficacy and Safety of ABP 710 Compared to Infliximab in Subjects With Moderate to Severe Rheumatoid Arthritis
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
South Australia
-
Woodville, South Australia, Australia, 5011
- Research Site
-
-
Victoria
-
Fitzroy, Victoria, Australia, 3065
- Research Site
-
-
-
-
-
Pleven, Bulgaria, 5800
- Research Site
-
Plovdiv, Bulgaria, 4003
- Research Site
-
Plovdiv, Bulgaria, 4002
- Research Site
-
Sliven, Bulgaria, 8800
- Research Site
-
Varna, Bulgaria, 9005
- Research Site
-
-
Sofiya
-
Sofia, Sofiya, Bulgaria, 1606
- Research Site
-
-
-
-
British Columbia
-
Victoria, British Columbia, Canada, V8V 3M9
- Research Site
-
-
Newfoundland and Labrador
-
Saint Johns, Newfoundland and Labrador, Canada, A1A 5E8
- Research Site
-
-
-
-
Jihormoravsky KRAJ
-
Brno, Jihormoravsky KRAJ, Czechia, 602 00
- Research Site
-
-
Moravskoslezsky
-
Hlučín, Moravskoslezsky, Czechia, 748 01
- Research Site
-
-
Praha
-
Praha 2, Praha, Czechia, 128 50
- Research Site
-
Praha 3, Praha, Czechia, 130 00
- Research Site
-
-
Severocesky KRAJ
-
Liberec, Severocesky KRAJ, Czechia, 460 01
- Research Site
-
-
Severomoravsky KRAJ
-
Ostrava, Severomoravsky KRAJ, Czechia, 702 00
- Research Site
-
Zlín, Severomoravsky KRAJ, Czechia, 760 01
- Research Site
-
-
Vychodocesky KRAJ
-
Pardubice, Vychodocesky KRAJ, Czechia, 530 02
- Research Site
-
-
-
-
-
Hamburg, Germany, 20095
- Research Site
-
-
Mecklenburg-vorpommern
-
Bad Doberan, Mecklenburg-vorpommern, Germany, 18209
- Research Site
-
-
Niedersachsen
-
Hildesheim, Niedersachsen, Germany, 31134
- Research Site
-
-
Sachsen-anhalt
-
Magdeburg, Sachsen-anhalt, Germany, 39120
- Research Site
-
-
-
-
Bekes
-
Gyula, Bekes, Hungary, 5700
- Research Site
-
-
Csongrad
-
Szentes, Csongrad, Hungary, 6600
- Research Site
-
-
Gyor-moson-sopron
-
Győr, Gyor-moson-sopron, Hungary, 9024
- Research Site
-
-
Veszprem
-
Veszprém, Veszprem, Hungary, 8200
- Research Site
-
-
-
-
Dolnoslaskie
-
Wroclaw, Dolnoslaskie, Poland, 50-381
- Research Site
-
-
Kujawsko-pomorskie
-
Bydgoszcz, Kujawsko-pomorskie, Poland, 85-168
- Research Site
-
Toruń, Kujawsko-pomorskie, Poland, 87-100
- Research Site
-
-
Lodzkie
-
Łódź, Lodzkie, Poland, 91-363
- Research Site
-
-
Lubelskie
-
Lublin, Lubelskie, Poland, 20-582
- Research Site
-
-
Malopolskie
-
Kraków, Malopolskie, Poland, 30-033
- Research Site
-
-
Mazowieckie
-
Warszawa, Mazowieckie, Poland, 01-192
- Research Site
-
Warszawa, Mazowieckie, Poland, 02-691
- Research Site
-
-
Podkarpackie
-
Stalowa Wola, Podkarpackie, Poland, 37-450
- Research Site
-
-
Podlaskie
-
Białystok, Podlaskie, Poland, 15-099
- Research Site
-
-
Pomorskie
-
Gdańsk, Pomorskie, Poland, 80-382
- Research Site
-
-
Slaskie
-
Katowice, Slaskie, Poland, 40-282
- Research Site
-
-
Warminsko-mazurskie
-
Elbląg, Warminsko-mazurskie, Poland, 82-300
- Research Site
-
-
Wielkopolskie
-
Poznan, Wielkopolskie, Poland, 60-693
- Research Site
-
Poznań, Wielkopolskie, Poland, 60-218
- Research Site
-
Poznań, Wielkopolskie, Poland, 60-529
- Research Site
-
Poznań, Wielkopolskie, Poland, 61-113
- Research Site
-
Poznań, Wielkopolskie, Poland, 61-397
- Research Site
-
-
-
-
-
Barcelona, Spain, 08028
- Research Site
-
Madrid, Spain, 28041
- Research Site
-
Sevilla, Spain, 41010
- Research Site
-
-
-
-
Alabama
-
Huntsville, Alabama, United States, 35801
- Research Site
-
Tuscaloosa, Alabama, United States, 35406
- Research Site
-
-
Arizona
-
Peoria, Arizona, United States, 85381
- Research Site
-
-
California
-
Covina, California, United States, 91722
- Research Site
-
Hemet, California, United States, 92543-4403
- Research Site
-
Upland, California, United States, 91786
- Research Site
-
Van Nuys, California, United States, 91405
- Research Site
-
-
Florida
-
Aventura, Florida, United States, 33180
- Research Site
-
Miami Lakes, Florida, United States, 33014
- Research Site
-
Orlando, Florida, United States, 32804
- Research Site
-
Sarasota, Florida, United States, 34239
- Research Site
-
Vero Beach, Florida, United States, 32960
- Research Site
-
-
Kentucky
-
Lexington, Kentucky, United States, 40504
- Research Site
-
-
Michigan
-
Grand Blanc, Michigan, United States, 48439
- Research Site
-
-
Mississippi
-
Flowood, Mississippi, United States, 39232
- Research Site
-
-
Missouri
-
Saint Louis, Missouri, United States, 63141
- Research Site
-
-
Nebraska
-
Omaha, Nebraska, United States, 68114
- Research Site
-
-
New Jersey
-
Voorhees, New Jersey, United States, 08043
- Research Site
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28210
- Research Site
-
-
South Carolina
-
Charleston, South Carolina, United States, 29406-9333
- Research Site
-
-
Tennessee
-
Memphis, Tennessee, United States, 38119
- Research Site
-
-
Texas
-
Carrollton, Texas, United States, 75007-1601
- Research Site
-
Dallas, Texas, United States, 75231
- Research Site
-
Houston, Texas, United States, 77429-5890
- Research Site
-
League City, Texas, United States, 77573
- Research Site
-
Plano, Texas, United States, 75024
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject (man or woman) is ≥ 18 and ≤ 80 years old.
- Subject is diagnosed with rheumatoid arthritis (RA) as determined by meeting the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism classification criteria for RA.
- Subject has RA duration of at least 3 months.
Subject has active RA defined as ≥ 6 swollen joints and ≥ 6 tender joints (based on 66/68 joint count excluding distal interphalangeal joints) at screening and baseline and at least 1 of the following at screening:
- erythrocyte sedimentation rate ≥ 28 mm/hr
- serum C-reactive protein > 1.0 mg/dL
- Subject has a positive rheumatoid factor or anti-cyclic citrullinated peptide at screening.
- Subject has taken methotrexate (MTX) for ≥ 12 consecutive weeks and is on a stable dose of oral or subcutaneous MTX 7.5 to 25 mg/week for ≥ 8 weeks before receiving the investigational product and is willing to remain on a stable dose throughout the study.
- For a subject on nonsteroidal anti-inflammatory drugs (NSAIDs) or low potency analgesics such as tramadol, Soma Compounds, Fioricet, or Fiorinal, the dose should be stable for ≥ 2 weeks before screening.
- For a subject on oral corticosteroids (≤ 10 mg prednisone or equivalent), the dose should be stable for ≥ 4 weeks before screening.
- Subject has no known history of active tuberculosis.
Subject has a negative test for tuberculosis during screening defined as either:
- negative purified protein derivative (PPD) defined as < 5 mm of induration at 48 to 72 hours after test is placed OR
- negative Quantiferon test
- Subject with a positive PPD and a history of Bacillus Calmette-Guérin vaccination is allowed with a negative Quantiferon test.
Subject with a positive PPD test (without a history of Bacillus Calmette-Guérin vaccination) or a subject with a positive or indeterminate Quantiferon test is allowed if they have all of the following:
- no symptoms of tuberculosis according to the worksheet provided by the sponsor, Amgen Inc.
- documented history of adequate prophylaxis initiation before receiving investigational product in accordance with local recommendations
- no known exposure to a case of active tuberculosis after most recent prophylaxis
Exclusion Criteria:
- Subject has a history of prosthetic or native joint infection.
Subject has an active infection or history of infections as follows:
- any active infection for which systemic anti-infectives were used within 28 days before first dose of investigational product
- a serious infection, defined as requiring hospitalization or intravenous (IV) anti-infective(s) within 8 weeks before the first dose of investigational product
- recurrent or chronic infections or other active infection that, in the opinion of the investigator, might cause this study to be detrimental to the subject
- Subject has a positive blood test for human immunodeficiency virus (HIV).
- Subject has a positive hepatitis B surface antigen, hepatitis B core antibody, or hepatitis C virus antibody result at screening.
- Subject has uncontrolled, clinically significant systemic disease such as diabetes mellitus, cardiovascular disease including moderate or severe heart failure (New York Heart Association Class III/IV), renal disease, liver disease, or hypertension.
- Subject had a malignancy within 5 years EXCEPT for treated and considered cured cutaneous squamous or basal cell carcinoma, in situ cervical cancer, OR in situ breast ductal carcinoma.
- Subject has a history of neurologic symptoms suggestive of central or peripheral nervous system demyelinating disease.
- Subject has a major chronic inflammatory disease or connective tissue disease other than RA, with the exception of secondary Sjögren's syndrome.
- Subject has a concurrent medical condition that, in the opinion of the investigator, could cause this study to be detrimental to the subject.
Subject has laboratory abnormalities at screening, including any of the following:
- hemoglobin < 9 g/dL
- platelet count < 100 000/mm³
- white blood cell count < 3 000/mm³
- aspartate aminotransferase and/or alanine aminotransferase ≥ 2.0 x the upper limit of normal
- creatinine clearance < 50 mL/min (Cockroft-Gault formula)
- any other laboratory abnormality, that, in the opinion of the investigator, will prevent the subject from completing the study or will interfere with the interpretation of the study results.
Subject has used commercially available or investigational biologic therapies for RA as follows:
- anakinra, etanercept within 1 month before the first dose of investigational product
- abatacept, tocilizumab, adalimumab, golimumab, certolizumab within 3 months before the first dose of investigational product
- other experimental or commercially available biologic therapies for RA within 3 months or 5 half-lives (whichever is longer) before the first dose of investigational product
- rituximab within 9 months before the investigational product along with evidence of incomplete B cell recovery
- Subject has received live vaccines within 28 days before the first dose of investigational product or plans to receive live vaccines during the course of the study.
- Subject has previously received Remicade® (infliximab) or a biosimilar of infliximab.
- Woman who is pregnant or breast feeding, or plans to become pregnant while enrolled in the study and for 6 months after the last dose of investigational product.
- Women of childbearing potential (ie, neither surgically sterile nor postmenopausal) and do not agree to use adequate contraception (eg, true abstinence, sterilization, birth control pills, Depo-Provera® [medroxyprogesterone] injections, or contraceptive implants) while on study and for 6 months after the last dose of investigational product.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ABP 710
Participants randomized to receive a 3 mg/kg intravenous (IV) infusion of ABP 710 on day 1, at weeks 2 and 6, and every 8 weeks thereafter until week 22. At week 22 participants continued receiving 3 mg/kg ABP 710 every 8 weeks through week 46. |
Administered by intravenous infusion
|
Active Comparator: Infliximab
Participants randomized to receive a 3 mg/kg IV infusion of infliximab on day 1, at weeks 2 and 6, and every 8 weeks thereafter until week 22. At week 22 participants were re-randomized in a 1:1 ratio to either continue receiving 3 mg/kg infliximab every 8 weeks or transition to receive 3 mg/kg ABP 710 every 8 weeks through week 46. |
Administered by intravenous infusion
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 22
Time Frame: Baseline and week 22
|
The primary efficacy endpoint was the response difference (RD) of 20% improvement in ACR core set measurements (ACR20) at week 22. A positive ACR20 response is defined if the following 3 criteria for improvement from baseline were met:
|
Baseline and week 22
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With an ACR20 Response Through Week 14
Time Frame: Baseline and weeks 2, 6, and 14
|
A positive ACR20 response is defined if the following 3 criteria for improvement from baseline were met:
|
Baseline and weeks 2, 6, and 14
|
Percentage of Participants With an ACR20 Response After Week 22
Time Frame: Baseline and weeks 30, 34, 38, 46, and 50
|
A positive ACR20 response is defined if the following 3 criteria for improvement from baseline were met:
|
Baseline and weeks 30, 34, 38, 46, and 50
|
Percentage of Participants With an ACR50 Response Through Week 22
Time Frame: Baseline and weeks 2, 6, 14, and 22
|
A positive ACR50 response is defined if the following 3 criteria for improvement from baseline were met:
|
Baseline and weeks 2, 6, 14, and 22
|
Percentage of Participants With an ACR50 Response After Week 22
Time Frame: Baseline and weeks 30, 34, 38, 46, and 50
|
A positive ACR50 response is defined if the following 3 criteria for improvement from baseline were met:
|
Baseline and weeks 30, 34, 38, 46, and 50
|
Percentage of Participants With an ACR70 Response Through Week 22
Time Frame: Baseline and weeks 2, 6, 14, and 22
|
A positive ACR70 response is defined if the following 3 criteria for improvement from baseline were met:
|
Baseline and weeks 2, 6, 14, and 22
|
Percentage of Participants With an ACR70 Response After Week 22
Time Frame: Baseline and weeks 30, 34, 38, 46, and 50
|
A positive ACR70 response is defined if the following 3 criteria for improvement from baseline were met:
|
Baseline and weeks 30, 34, 38, 46, and 50
|
Change From Baseline in Disease Activity Score 28 (DAS28) Through Week 22
Time Frame: Baseline and weeks 2, 6, 14, and 22
|
The DAS28 measures the severity of disease at a specific time and is derived from the following variables:
DAS28(CRP) scores range from 0 to approximately 10, with the upper bound dependent on the highest possible level of CRP. A DAS28 score higher than 5.1 indicates high disease activity, a DAS28 score less than 3.2 indicates low disease activity, and a DAS28 score less than 2.6 indicates clinical remission. |
Baseline and weeks 2, 6, 14, and 22
|
Change From Baseline in Disease Activity Score 28 (DAS28) After Week 22
Time Frame: Baseline and weeks 30, 34, 38, 46, and 50
|
The DAS28 measures the severity of disease at a specific time and is derived from the following variables:
DAS28(CRP) scores range from 0 to approximately 10, with the upper bound dependent on the highest possible level of CRP. A DAS28 score higher than 5.1 indicates high disease activity, a DAS28 score less than 3.2 indicates low disease activity, and a DAS28 score less than 2.6 indicates clinical remission. |
Baseline and weeks 30, 34, 38, 46, and 50
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20140111
- 2014-004704-29 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Arthritis, Rheumatoid
-
Janssen Research & Development, LLCWithdrawnActive Rheumatoid Arthritis; Rheumatoid Arthritis
-
Centocor, Inc.CompletedRheumatoid Arthritis, Juvenile
-
AmgenTerminated
-
Children's Hospital Medical Center, CincinnatiNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedJuvenile Rheumatoid ArthritisUnited States
-
AmgenImmunex CorporationCompletedJuvenile Rheumatoid Arthritis
-
National Institute of Arthritis and Musculoskeletal...Children's Hospital Medical Center, CincinnatiCompleted
-
University of PittsburghNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedRheumatoid Arthritis | Juvenile Rheumatoid ArthritisUnited States
-
University of Missouri-ColumbiaCompletedJuvenile Rheumatoid ArthritisUnited States
-
Assistance Publique - Hôpitaux de ParisSociete Francaise de RhumatologieRecruiting
-
Amsterdam UMC, location VUmcEuropean CommissionCompletedRheumatoId ArthritisNetherlands, Germany, Portugal, Italy, Hungary, Romania, Slovakia
Clinical Trials on ABP 710
-
4D Molecular TherapeuticsRecruiting
-
Assistance Publique Hopitaux De MarseilleCompleted
-
Laval UniversityActive, not recruitingMetabolic Syndrome | Gut MicrobiotaCanada
-
Jiangsu Atom Bioscience and Pharmaceutical Co.,...CompletedGout | Food-drug InteractionUnited States
-
Jiangsu Atom Bioscience and Pharmaceutical Co.,...CompletedHyperuricemia | GoutUnited States
-
Jiangsu Atom Bioscience and Pharmaceutical Co.,...Recruiting
-
Jiangsu Atom Bioscience and Pharmaceutical Co.,...CompletedHyperuricemia | GoutAustralia
-
Jiangsu Atom Bioscience and Pharmaceutical Co.,...CompletedHyperuricemia | GoutUnited States
-
AEON Biopharma, Inc.PPDEnrolling by invitationMigraineUnited States, Australia, Canada
-
AEON Biopharma, Inc.PPDCompletedCervical DystoniaUnited States